Pharmacological modulators of voltage-gated calcium channels and their therapeutical application

Cell Calcium

Volumn 33, Issue 3, 2003, Pages 145-162

  Kochegarov, Andrei A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium antagonist; Calcium channel; Calcium channel blocker; Voltage gated calcium channel

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2,6 DIHYDROXYPYRIDINE; 4 (2,1,3 BENZOOXADIAZOL 4 YL) 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; AMLODIPINE BESYLATE; BENZOTHIAZEPINE DERIVATIVE; CALAN SR; CALCISEPTINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CLEVIDIPINE; DILTIAZEM; FELODIPINE; HORMONE; IGANIDIPINE; ISRADIPINE; LACIDIPINE; MIBEFRADIL; MYOSIN ADENOSINE TRIPHOSPHATASE; NEUROTRANSMITTER; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIC; PHENYLALKYLAMINE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WATANIDIPINE;

ACTION POTENTIAL; ALLERGY; ALZHEIMER DISEASE; ASTHMA; BLOOD PRESSURE REGULATION; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CHANNEL GATING; CLUSTER HEADACHE; CYTOSOL; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; GLAUCOMA; HEART INFARCTION; HORMONE RELEASE; HUMAN; MALE INFERTILITY; MEMBRANE DEPOLARIZATION; MIGRAINE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NERVE CELL; NEUROTRANSMITTER RELEASE; PAIN; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SENSOR; SIGNAL TRANSDUCTION; STROKE; VASCULAR SMOOTH MUSCLE;

EID: 0037342572     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4160(02)00239-7     Document Type: Review

References (178)

1. E.A. Ertel, K.P. Campbell, M.M. Harpold, F. Hofmann, et al., Nomenclature of voltage-gated calcium channels, Neuron 25 (3) (2000) 533-535 (letter).
2. Y.M.C. Nowyck, A.P. Fox, R.W. Tsien, Three types of neuronal calcium channel with different calcium agonist sensitivity, Nature 316 (1985) 440-446.
3. 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels, Nat. Neurosci. 2 (1999) 407-415.
4. 2+ channels, Neuron 9 (1992) 69-77.
5. 2+ channels and their possible counterparts in mammalian CNS neurons, Neuropharmacology 32 (1993) 1075-1088.
6. A. Tottene, A. Moretti, D. Pietrobon, Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons, J. Neurosci. 16 (1996) 6353-6363.
7. 2+ channels are coupled to the rapid component of secretion in mouse adrenal slice chromaffin cells, J. Neurosci. 20 (2000) 8323-8330.
8. 2+ currents evoke transmitter release at a rat central synapse, Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4720-4725.
9. 2+ channels and insulin secretion in the insulinoma cell line INS-1, Eur. J. Biochem. 268 (2001) 1066-1075.
10. R. Newcomb, B. Szoke, A. Palma, G. Wang, Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas, Biochemistry 37 (44) (1998) 15353-15362.
11. R. Newcomb, X. Chen, R. Dean, G. Dayanithi, et al., SNX-482: a novel class E calcium channel antagonist from tarantula venom, CNS Drug Rev. 6 (2) (2000) 153-173.
12. L. Lacinová, N. Klugbauer, F. Hofmann, Regulation of the calcium channel alpha(1G) subunit by divalent cations and organic blockers, Neuropharmacology 39 (7) (2000) 1254-1266.
13. M. Kohlhardt, B. Bauer, H. Krause, A. Fleckenstein, Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibres by the use of specific inhibitors, Pflugers Arch. Eur. J. Physiol. 335 (4) (1972) 309-322.
14. H. Kusuoka, M.C. Corretti, Y. Koretsune, E. Marban, Mechanism for the cardioprotective effects of the calcium channel blocker clentiazem during ischemia and reperfusion, Jpn. Circ. J. 62 (8) (1998) 611-616.
15. G.C. Rovnyak, S.D. Kimball, B. Beyer, G. Cucinotta, et al., Calcium entry blockers; and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators, J. Med. Chem. 38 (1) (1995) 119-129.
16. D.J. Triggle, D. Rampe, 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions, Trends Pharmacol. Sci. 10 (12) (1989) 507-511.
17. P. Hess, J.B. Lansman, R.W. Tsien, Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists, Nature 311 (1984) 538-544.
18. S. Hering, S. Berjukov, S. Aczel, E.N. Timin, Calcium channel block and inactivation: common molecular determinants, Trends Pharmacol. Sci. 19 (1998) 434-439.
19. J. Striessnig, M. Grabner, J. Mitterdorfer, S. Hering, et al., Structural basis of drug binding to L calcium channels, Trends Pharmacol. Sci. 19 (1998) 108-115.
20. M.C. Sanguinetti, R.S. Kass, Voltage-dependent block of calcium channel current in calf Purkinje fiber by dihydropyridine calcium channel antagonists, Circ. Res. 55 (1984) 336-348.
21. S. Hering, S. Aczél, R.L. Kraus, S. Berjukow, Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation, Proc. Natl. Acad. Sci. U.S.A. 94 (24) (1997) 13323-13328.
22. 2+ channels, Mol. Pharmacol. 58 (6) (2000) 1264-1270.
23. 2+ channels, Circ. Res. 81 (4) (1997) 526-532.
24. T. Godfraind, et al., Selectivity of calcium antagonists in the human cardiovascular system based on in vitro studies, J. Cardiovasc. Pharmacol. 20 (Suppl. 5) (1992) S34-S41.
25. P.H. Held, S. Yusuf, Effects of beta-blockers and calcium channel blockers in acute myocardial infarction, Eur. Heart J. 4A (Suppl. F) (1993) 18-25.
26. U. Elkayam, A. Shotan, A. Mehra, E. Ostrzega, Calcium channel blockers in heart failure, J. Am. Coll. Cardiol. 4 (Suppl. A) (1993) 139A-144A.
27. R.F. Raspa, C.C. Wilson, Calcium channel blockers; in the treatment of hypertension, Am. Fam. Physician 48 (3) (1993) 461-470.
28. R.J. Straka, A.L. Wanson, Calcium channel antagonists: morbidity and mortality-what's the evidence? Am. Acad. Fam. Physicians 57 (7) (1998) 1551-1560.
29. T. Toyo-Oka, W.G. Nayler, Third generation calcium entry blockers, Blood Press. 5 (4) (1996) 206-208.
30. 19F-NMR spectroscopy, Magn. Reson. Imaging 18 (8) (2000) 1011-1016.
31. T. Mori, H. Takase, K. Toide, T. Hirano, et al., Pranidipine, a 1,4-dihydropyridine calcium channel blocker that enhances nitric oxide-induced vascular relaxation, Cardiovasc. Drug Rev. 19 (1) (2001) 1-8.
32. T. Mori, T. Takeuchi, M. Ohura, G. Miyakoda, Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta, Mol. Cell. Biochem. 178 (1/2) (1998) 335-343.
33. M. Nishikawa, Y. Kubo, H. Kido, T. Nakayama, N. Nakamura, Protection against endothelial abnormalities by a novel calcium channel blocker, AE0047, in stroke-prone spontaneously hypertensive rats, Gen. Pharmacol. 32 (3) (1999) 299-305.
34. H. Shirahase, K. Wada, Y. Uehara, S. Nakamura, A. Ichikawa, Preventive effect of iganidipine on renal and cerebral injuries in salt-induced hypertension, Am. J. Hypertens. 10 (8) (1997) 869-878.
35. M. Waki, T. Sugiyama, N. Watanabe, T. Ogawa, et al., Effect of topically applied iganidipine dihydrochloride, a novel calcium antagonist, on optic nerve head circulation in rabbits, Jpn J. Ophthalmol. 45 (1) (2001) 76-83.
36. T. Yamamoto, Y. Niwa, H. Kawakami, Y. Kitazawa, The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma, J. Glaucoma 7 (5) (1998) 301-305.
37. M. Kawabata, T. Ogawa, T. Takabatake, Effects of lemildipine, a new calcium channel blocker, on renal microcirculation in SHR, Hypertens. Res. 21 (2) (1998) 121-126.
38. K. Ichihara, K. Okumura, H. Kamei, M. Nagasaka, Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats, J. Cardiovasc. Pharmacol. 31 (2) (1998) 277-285.
39. R. Ho, D. Ortiz, T.B. Shea, Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons, J. Alzheimer Dis. 3 (5) (2001) 479-483.
40. U. Kanwar, R.J. Anand, S.N. Sanyal, The effect of nifedipine, a calcium channel blocker, on human spermatozoal functions, Contraception 48 (5) (1993) 453-470.
41. S. Benoff, G.W. Cooper, I. Hurley, F.S. Mandel, The effect of calcium ion channel blockers on sperm fertilization potential, Fertil. Steril. 62 (3) (1994) 606-617.
42. L.A. Levine, P.F. Merrick, R.C. Lee, Intralesional verapamil injection for the treatment of Peyronie's disease, J. Urol. 151 (6) (1994) 1522-1524.
43. R.C. Lee, J.A. Ping, Calcium antagonists retard extracellular matrix production in connective tissue equivalent, J. Surg. Res. 49 (1990) 463-466.
44. H. Doong, T.R. Dissanayake, M.C. Labarbera, et al., Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts, J. Burn Care Rehab. 17 (1996) 497-514.
45. P. Cristofori, A. Lanzoni, M. Quartaroli, A.M. Pastorino, et al., The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse, J. Hypertens. 18 (10) (2000) 1429-1436.
46. M. Leone, D. D'Amico, F. Frediani, F. Moschiano, Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo, Neurology 54 (6) (2000) 1382-1385.
47. L.E. Hollister, E.S.G. Trevino, Calcium channel blockers in psychiatric disorders: a review of the literature, Can. J. Psychiatry 44 (1999) 658-664.
48. F. Hoffmeister, D. Tettenborn, Calcium agonists and antagonists of the dihydropyridine type: antinociceptive effects, interference with opiate-mu-receptor agonists and neuropharmacological actions in rodents, Psychopharmacology 90 (3) (1986) 299-307.
49. D.B. Vaupel, W.R. Lange, E.D. London, Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans, J. Pharmacol. Exp. Ther. 267 (3) (1993) 1386-1394.
50. P. Dayer, J. Desmeules, L. Collart, Pharmacology of tramadol, Drugs 53 (Suppl. 2) (1997) 18-24.
51. M.C. Gupta, S.K. Garg, Effect of nimodipine, a dihydropyridine calcium channel antagonist, on the steady state pharmacokinetics of phenytoin (DPH) in rhesus monkeys, Methods Find. Exp. Clin. Pharmacol. 21 (6) (1999) 453-455.
52. D. Edelman, R.A. Paul, Does combination therapy with a calcium channel blocker and an ACE inhibitor have additive effects on blood pressure reduction? Int. J. Clin. Pract. 54 (2) (2000) 105-109.
53. Z.G. Ye, K. Van Dyke, Reversal of chloroquine resistance in falciparum malaria independent of calcium channels, Biochem. Biophys. Res. Commun. 155 (1) (1988) 476-481.
54. R. Gross, M. Kayser, M. Schramm, R. Taniel, G. Thomas, Cardiovascular effects of the calcium-agonistic dihydropyridine BAY K 8644 in conscious dogs, Arch. Int. 277 (2) (1985) 203-216.
55. R.C. Shelton, J.A. Grebb, W.J. Freed, Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644, Brain Res. 402 (1987) 399-402.
56. J. Von Wegerer, B. Hesslinger, M. Berger, J. Walden, A calcium antagonistic effect of the new antiepileptic drug lamotrigine, Eur. Neuropsychopharmacol. 7 (2) (1997) 77-81.
57. K. Schirrmacher, A. Mayer, J. Walden, R. Düsing, Effect of carbamazepine on action potentials and calcium currents in rat spinal ganglion cells in vitro, Neuropsychobiology 27 (1993) 176-179.
58. A. Stefani, A.H. Hainsworth, F. Spadoni, G. Bernardi, On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89, Br. J. Pharmacol. 125 (5) (1998) 1058-1064.
59. 2+ channels by the neuroprotective agent BW619C89 (Sipatrigine), Neuropharmacology 39 (7) (2000) 1247-1253.
60. 2+ channels by the neuroprotective agent BW619C89, Neuropharmacology 36 (11/12) (1997) 1795-1798.
61. 2+ channel blockade by a novel neuroprotective agent NS-7, Pharmacol. Toxicol. 89 (3) (2001) 123-128.
62. L. Caputi, A.H. Hainsworth, F. Lavaroni, M.J. Leach, N.C. McNaughton, N.B. Mercuri, A.D. Randall, F. Spadoni, J.H. Swan, A. Stefani, Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92, Brain Res. 919 (2) (2001) 259-268.
63. S. Gubert, M.A. Brasó, A. Sacristán, J.A. Ortiz, Synthesis of some N-benzhydrylpiperazine derivatives as calcium antagonists, Arzneimittelforschung 37 (10) (1987) 1103-1107.
64. J. Tytgat, P. Pauwels, J. Vereecke, E. Carmeliet, Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons, Brain Res. (1991) 17; 549 (1) 112-117.
65. 2+ channels, Naunyn Schmiedebergs Arch. Pharmacol. 337 (1988) 690-692.
66. N. Akaike, P.G. Kostyuk, Y.V. Osipchuk, Dihydropyridine-sensitive low-threshold calcium channels in isolated hypothalamic neurones, J. Physiol. (Lond.) 412 (1989) 181-195.
67. A. Ruiz-Nuño, M. Villarroya, M. Cano-Abad, A. Rosado, et al., Mechanisms of blockade by the novel migraine prophylactic agent dotarizine of various brain and peripheral vessel contractility, Eur. J. Pharmacol. 411 (3) (2001) 289-299.
68. G.S. Schierle, P. Brundin, Excitotoxicity plays a role in the death of tyrosine hydroxylase-immunopositive nigral neurons cultured in serum-free medium, Exp. Neurol. 157 (1999) 338-348.
69. M.E. Eichler, J. Dubinsky, J. Tong, K.M. Rich, The ability of diphenylpiperazines to prevent neuronal death in dorsal root ganglion neurons in vitro after nerve growth factor deprivation and in vivo after axotomy, J. Neurochem. 62 (1994) 2148-2157.
70. T. Gonçalves, A.P. Carvalho, C.R. Oliveira, Antioxidant effect of calcium antagonists on microsomal membranes isolated from different brain areas, Eur. J. Pharmacol. 204 (1991) 315-322.
71. B.J. Alps, C. Calder, W.K. Hass, A.D. Wilson, Comparative protective effects of nicardipine flunarizine lidoflazine and nimodipine against ischaemic injury in the hippocampus of Mongolian gerbil, Br. J. Pharmacol. 93 (1988) 877-883.
72. 2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina, Exp. Eye Res. 70 (4) (2000) 475-484.
73. +-ATPase in catecholamine storage vesicles, Neuropharmacology 38 (6) (1999) 879-882.
74. K. Haraguchi, K. Ito, H. Kotaki, Y. Sawada, T. Iga, Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies, Drug Metab. Dispos. 25 (6) (1997) 675-684.
75. 2+ channel blocker, Cardiovasc. Drug Rev. 19 (4) (2001) 279-296.
76. J. García, K.G. Beam, Calcium transients associated with the T type calcium current in myotubes, J. Gen. Physiol. 104 (6) (1994) 1113-1128.
77. R.J. Lewis, K.J. Nielsen, D.J. Craik, M.L. Loughnan, Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes, J. Biol. Chem. 275 (45) (2000) 35335-35344.
78. C.A. Ramilo, G.C. Zafaralla, L. Nadasdi, L.G. Hammerland, et al., Novel alpha- and omega-conotoxins from Conus striatus venom, Biochemistry 31 (41) (1992) 9919-9926.
79. B.M. Olivera, Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology, Mol. Biol. Cell 8 (1997) 2101-2109.
80. R.M. Jones, G.E. Cartier, J.M. Mcintosh, G. Bulay, et al., Composition and therapeutic utility of conotoxins from genus Conus, Exp. Opin. Ther. Patents 11 (4) (2001) 603-623.
81. K.A. Sluka, Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats, Pain 71 (2) (1997) 157-164.
82. J. Nebe, H. Vanegas, H.G. Schaible, Spinal application of omega-conotoxin GVIA, an N-type calcium channel antagonist, attenuates enhancement of dorsal spinal neuronal responses caused by intra-articular injection of mustard oil in the rat, Exp. Brain Res. 120 (1) (1998) 61-69.
83. K. Valentino, R. Newcomb, T. Gadbois, T. Singh, et al., A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia, Proc. Natl. Acad. Sci. U.S.A. 90 (16) (1993) 7894-7897.
84. T.R. Ryder, L.Y. Hu, M.F. Rafferty, E. Millerman, B.G. Szoke, K. Tarczy-Hornoch, Multiple parallel synthesis of N,N-dialkyl-dipeptidylamines as N-type calcium channel blockers, Bioorg. Med. Chem. Lett. 9 (13) (1999) 1813-1818.
85. T.R. Ryder, L.Y. Hu, M.F. Rafferty, S.M. Lotarski, D.M. Rock, S.J. Stoehr, C.P. Taylor, M.L. Weber, G.P. Miljanich, E. Millerman, B.G. Szoke, Structure-activity relationship at the leucine side chain in a series of N,N-dialkyldipeptidyl-amines as N-type calcium channel blockers, Drug Des. Discov. 16 (4) (2000) 317-322.
86. A.G. Craig, T. Norberg, D. Griffin, C. Hoeger, Contulakin-G, an O-glycosylated invertebrate neurotensin, J. Biol. Chem. 274 (20) (1999) 13752-13759.
87. M. Fainzilber, J.C. Lodder, R.C. Van Der Schors, K.W. Li, A novel hydrophobic omega-conotoxin blocks molluscan dihydropyridine-sensitive calcium channels, Biochemistry 35 (26) (1996) 8748-8752.
88. K. Kobayashi, T. Sasaki, K. Sato, T. Kohno, Three-dimensional solution structure of omega-conotoxin TxVII, an L-type calcium channel blocker, Biochemistry 39 (48) (2000) 14761-14767.
89. M. Ori, H. Ikeda, Spider venoms and spider toxins, J. Toxicol. 17 (3) (1998) 405-426.
90. 2+ channel subtypes in cultured rat hippocampal neurons, Mol. Pharmacol. 48 (1) (1995) 131-139.
91. S.I. McDonough, R.A. Lampe, R.A. Keith, B.P. Bean, Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA, Mol. Pharmacol. 52 (6) (1997) 1095-1104.
92. R. Newcomb, B. Szoke, A. Palma, G. Wang, Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas, Biochemistry 37 (44) (1998) 15353-15362.
93. L. Yan, M.E. Adams, The spider toxin omega-Aga IIIA defines a high affinity site on neuronal high voltage-activated calcium channels, J. Biol. Chem. 275 (28) (2000) 21309-21316.
94. S.I. McDonough, L.M. Boland, I.M. Mintz, B.P. Bean, Interactions among toxins that inhibit N-type and P-type calcium channels, J. Gen. Physiol. 119 (4) (2002) 313-328.
95. M.E. Adams, I.M. Mintz, M.D. Reily, V. Thanabal, B.P. Bean, Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels, Mol. Pharmacol. 44 (4) (1993) 681-688.
96. T. Teramoto, M. Kuwada, T. Niidome, K. Sawada, A novel peptide from funnel web spider venom, omega-Aga-TK, selectively blocks, P-type calcium channels, Biochem. Biophys. Res. Commun. 196 (1) (1993) 134-140.
97. K. Hagiwara, K. Sakai, A. Miwa, T. Nakajima, Complete amino acid sequence of a new type of neurotoxin from the venom of the spider Agelena opulenta, Biomed. Res. 11 (1990) 181.
98. C.W. Bowers, H.S. Phillips, P. Lee, Y.N. Jan, L.Y. Jan, Identification and purification of an irreversible presynaptic neurotoxin from the venom of the spider Hololena curta, Proc. Natl. Acad. Sci. U.S.A. 84 (10) (1987) 3506-3510.
99. H.T. Leung, L. Byerly, Characterization of single calcium channels in Drosophila embryonic nerve and muscle cells, J. Neurosci. 11 (10) (1991) 3047-3059.
100. 2+ channel in rat synaptosomes by venom of the spider Hololena curta, Eur. J. Pharmacol. 225 (1) (1992) 51-56.
101. 2+ channel inhibitors in venom of the spider Plectreurys tristis, Toxicon 31 (10) (1993) 1249-1256.
102. J. Bódi, H. Nishio, Y. Zhou, W.D. Branton, et al., Synthesis of an O-palmitoylated 44-residue peptide amide (PLTX II) blocking presynaptic calcium channels in Drosophila, Pept. Res. 8 (4) (1995) 228-235.
103. 2+ channels in differentiated NG108-15 cells, a patch-clamp study, Toxicon 39 (4) (2001) 491-498.
104. D.M. Yoshioka, T. Chiba, M. Matsukawa, M. Nishimura, T. Akizawa, Diversity of joro spider toxins, Cyber Cong. Anal. BioSci. (1997).
105. R.G. Santos, C.R. Diniz, M.N. Cordeiro, M.E. De Lima, Binding sites and actions of Tx1, a neurotoxin from the venom of the spider Phoneutria nigriventer, in guinea pig ileum, Braz. J. Med. Biol. Res. 32 (12) (1999) 1565-1569.
106. J. Sullivan, E.M. Lasater, Sustained and transient calcium currents in horizontal cells of the white bass retina, J. Gen. Physiol. 99 (1) (1992) 84-107.
107. O. Yasuda, S. Morimoto, B. Jiang, H. Kuroda, et al., FS2: a mamba venom toxin, is a specific blocker of the L-type calcium channels, Artery 21 (5) (1994) 287-302.
108. Weille De Jr., H. Schweitz, P. Maes, A. Tartar, M. Lazdunski, Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel, Proc. Natl. Acad. Sci. U.S.A. 88 (6) (1991) 2437-2440.
109. O. Yasuda, S. Morimoto, Y. Chen, B. Jiang, et al., Calciseptine binding to a 1,4-dihydropyridine recognition site of the L-type calcium channel of rat synaptosomal membranes, Biochem. Biophys. Res. Commun. 194 (2) (1993) 587-594.
110. 2+ channels with a high affinity for L-type channels in cerebellar granule neurons, Proc. Natl. Acad. Sci. U.S.A. 91 (3) (1994) 878-882.
111. A.M. Brown, A. Yatani, A.E. Lacerda, G.B. Gurrola, L.D. Possani, Neurotoxins that act selectively on voltage-dependent cardiac calcium channels, Circ. Res. 61 (4 Pt 2) (1987) I6-I9.
112. L.D. Possani, B.M. Martin, A. Yatani, J. Mochca-Morales, et al., Isolation and physiological characterization of taicatoxin, a complex toxin with specific effects on calcium channels, Toxicon 30 (11) (1992) 1343-1364.
113. E. Fantini, P. Athias, R. Tirosh, A. Pinson, Effect of TaiCatoxin (TCX) on the electrophysiological, mechanical and biochemical characteristics of spontaneously beating ventricular cardiomyocytes, Mol. Cell. Biochem. 160/161 (1996) 61-66.
114. C.J. Cohen, S. Spires, D. Van Skiver, Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists, J. Gen. Physiol. 100 (4) (1992) 703-728.
115. 2+ release processes of rabbit heart mitochondria in vitro, J. Pharmacol. Exp. Ther. 233 (2) (1985) 376-381.
116. S. Nagashima, T. Uematsu, S. Araki, T. Matsuzaki, Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta, J. Pharmacol. Exp. Ther. 234 (1) (1985) 63-71.
117. E.J. Lehning, R. Doshi, N. Isaksson, P.K. Stys, R.M. Lopachin, Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of reverse sodium-calcium exchange, J. Neurochem. 66 (2) (1996) 493-500.
118. J.A. Wolf, P.K. Stys, T. Lusardi, D. Meaney, D.H. Smith, Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels, J. Neurosci. 21 (6) (2001) 1923-1930.
119. 2+ channels and anoxic injury in rat CNS white matter, J. Neurophysiol. 85 (2) (2001) 900-911.
120. J.P. Clozel, E.A. Ertel, S.I. Ertel, Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker, J. Hypertens. Suppl. 15 (5) (1997) S17-S25.
121. S.T. Sandmann, T. Unger, L- and T-type calcium channel blockade-the efficacy of the calcium channel antagonist mibefradil, J. Clin. Basic Cardiol. 2 (1999) 187.
122. 2+ channel blocker with potent vasodilator but weak inotropic action, J. Cardiovasc. Pharmacol. 13 (1889) 754-759.
123. S. Sandmann, R.M. Bohle, T. Dreyer, T. Unger, The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats, Virchows Arch. 436 (2) (2000) 147-157.
124. R.P. Mason, I.T. Mak, M.F. Walter, T.N. Tulenko, P.E. Mason, Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil, Biochem. Pharmacol. 55 (11) (1998) 1843-1852.
125. +-induced force and block of L-type calcium current in rat cerebral arteries, J. Physiol. 508 (Pt 3) (1998) 793-800.
126. E. Del Pozo, J.M. Baeyens, Effects of calcium channel of blockers on neuromuscular blockade induced by aminoglycoside antibiotics, Eur. J. Pharmacol. 128 (1/2) (1986) 49-54.
127. A.G. Paradelis, C.J. Triantaphyllidis, M. Mironidou, L.G. Crassaris, et al., Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions, Methods Find. Exp. Clin. Pharmacol. 10 (11) (1988) 687-690.
128. 125I]-omega-conotoxin GVIA binding to guinea-pig cerebral cortex membranes, Naunyn Schmiedebergs Arch. Pharmacol. 336 (5) (1987) 583-586.
129. I.J. Reynolds, R.J. Gould, S.H. Snyder, Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects, J. Pharmacol. Exp. Ther. 231 (3) (1984) 628-632.
130. L.A. Ooms, A.D. Degryse, P.A. Janssen, Mechanisms of action of loperamide, Scand. J. Gastroenterol. Suppl. 96 (1984) 145-155.
131. J. Church, E.J. Fletcher, K. Abdel-Hamid, J.F. Macdonald, Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons, Mol. Pharmacol. 45 (4) (1994) 747-757.
132. P. Chan, W.T. Chin, Y.J. Chen, P.J. Wu, J.T. Cheng, Calcium influx inhibition: possible mechanism of the negative effect of tetrahydropaimatine on left ventricular pressure in isolated rat heart, Planta Med. 65 (4) (1999) 340-342.
133. 2+ mobilization in rat glioma C6 cells, Res. Commun. Mol. Pathol. Pharmacol. 95 (2) (1997) 129-149.
134. + channels, Life Sci. 56 (5) (1995) 295-306.
135. H. Dong, M.L. Earle, Y. Jiang, K.A. Loutzenhiser, C.R. Triggle, Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure, Br. J. Pharmacol. 122 (7) (1997) 1271-1278.
136. J. Chan, D.A. Greenberg, SK&F 96365, a receptor-mediated calcium entry inhibitor, inhibits calcium responses to endothelin-1 in NG108-15 cells, Biochem. Biophys. Res. Commun. 177 (3) (1991) 1141-1146.
137. J.E. Merritt, W.P. Armstrong, C.D. Benham, T.J. Hallam, et al., SK&F 96365, a novel inhibitor of receptor-mediated calcium entry, Biochem. J. 271 (2) (1990) 515-522.
138. P. Collins, C.M. Beale, G.M. Rosano, Oestrogen as a calcium channel blocker, Eur. Heart J. 17 (Suppl. D) (1996) 27-31.
139. M. Farhat, M. Lavigne, P. Ramwell, The vascular protective effects of estrogen, FASEB J. 10 (1996) 615-624.
140. J.C. Boyer, R. Magous, M.O. Christen, J.L. Balmes, J.P. Bali, Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium, bromide, Cell Calcium 29 (6) (2001) 429-438.
141. M. Bouchoucha, A. Faye, G. Devroede, M. Arsac, Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients, Biomed. Pharmacother. 54 (7) (2000) 381-387.
142. 2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents, J. Neurophysiol. 79 (1) (1998) 240-252.
143. 2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists, Neuropharmacology 38 (9) (1999) 1349-1359.
144. J.M. Doughty, A.L. Miller, P.D. Langton, Non-specificity of chloride channel blockers in rat cerebral arteries: block of the L-type calcium channel, J. Physiol. 507 (Pt 2) (1998) 433-439.
145. D. Rampe, A.E. Lacerda, A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176, J. Pharmacol. Exp. Ther. 259 (3) (1991) 982-987.
146. 2+ channel activator, in cardiac and vascular preparations, Mol. Pharmacol. 40 (5) (1991) 734-741.
147. S.B. Freedman, R.J. Miller, D.M. Miller, D.R. Tindall, Interactions of maitotoxin with voltage-sensitive calcium channels in cultured neuronal cells, Proc. Natl. Acad. Sci. U.S.A. 81 (14) (1984) 4582-4585.
148. 2+ channel activator candidate, J. Biol. Chem. 257 (13) (1982) 7287-7289.
149. F. Gusovsky, J.W. Daly, Maitotoxin: a unique pharmacological tool for research on calcium-dependent mechanisms, Biochem. Pharmacol. 39 (1990) 1633-1639.
150. D. Xi, F.M. Van Dolah, J.S. Ramsdell, Maitotoxin induces a voltage dependent membrane depolarization in GH4 pituitary cells via activation of type L voltage dependent calcium channels, J. Biol. Chem. 267 (1992) 25025-25031.
151. 2+ channel subunits, J. Pharmacol. Exp. Ther. 290 (2) (1999) 725-730.
152. J.G. Jollis, R.J. Simpson Jr., M.K. Chowdhury, W.E. Cascio, et al., Calcium channel blockers and mortality in elderly patients with myocardial infarction, Arch. Intern. Med. 159 (19) (1999) 2341-2348.
153. J.R. Kizer, S.E. Kimmel, Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards, Arch. Intern. Med. 161 (9) (2001) 1145-1158.
154. P. Lyden, N.G. Wahlgren, Mechanisms of action of neuroprotectants in stroke, J. Stroke Cerebrovasc. Dis. 9 (6, Suppl. 2) (2000) 9-14.
155. T. Igarashi, S. Aritake, T. Yasumoto, Mechanisms underlying the hemolytic and ichthyotoxic activities of maitotoxin, Nat. Toxins 7 (2) (1999) 71-79.
156. H. Liu, S. Peng, Y. Shen, W. Song, The cytotoxicity of maitotoxin to LLC-PK(1) and its antagonism to calcium channel blocking agents, Zhonghua Yu Fang Yi Xue Za Zhi 36 (1) (2002) 22-24 (in Chinese).
157. 2+ channel blockers and kinases, Cell Signal. 13 (10) (2001) 711-716.
158. H.M. Brereton, J. Chen, G. Rychkov, M.L. Harland, G.J. Barritt, Maitotoxin activates an endogenous non-selective cation channel and is an effective initiator of the activation of the heterologously expressed hTRPC-1 (transient receptor potential) non-selective cation channel in H4-IIE liver cells, Biochim. Biophys. Acta 1540 (2) (2001) 107-126.
159. L. Olivi, J. Bressler, Maitotoxin stimulates Cd influx in Madin-Darby kidney cells by activating Ca-permeable cation channels, Cell Calcium 27 (4) (2000) 187-193.
160. Lab L Lafon, 1-4-Dihydropyridines with pyridinyl group as calcium blockers, Patent WO0003712-A (2000).
161. Lab L Lafon; & et al., 1,4-Dihydropyridines as calcium blockers, Patent WO0003987-A (2000).
162. Lab L Lafon; & et al., 1-4-Dihydropyridines with benzodioxo carbonyl group as calcium blockers, Patent WO0004015-A (2000).
163. UCP Japan KK, Treatment for heart failure, Patent JP12309535-A (2000).
164. Ajinomoto Co. Inc., Dihydropyridine derivative, Patent WO0078719-A (2000).
165. Ajinomoto Co. Inc., Novel dihydropyridine derivative, Patent WO0078720-A (2000).
166. Ajinomoto Co. Inc., Novel dihydropyridine derivative, Patent WO0078730-A (2000).
167. Ajinomoto Co. Inc., Novel dihydropyridine derivatives as N-type calcium channel blockers, Patent WO9849144 (1998).
168. Ajinomoto Co. Inc., Novel dihydropyridine derivative, Patent (1999).
169. Ajinomoto Co. Inc., Dihydropyridine derivatives and drug compositions containing the same, Patent (2000).
170. Ortho-McNeil Pharm, Inc., Dithiepino[6,5-b]pyridines, and related compositions and methods, Patent WO0077009-A (2000).
171. Nippon Shinyaku Co. Ltd., Calcium channel antagonists which comprise a pyrimidine derivative which blocks P/Q channels and which inhibit neurotransmitter release, Patent WO0010571-A (2000).
172. Astra, Compounds: novel 2-alkylheterodihydropyrimidines, Patent WO9901437-A (1999).
173. Astra, Novel 3,4-dihydropyrimidines, Patent WO9901438-A (1999).
174. Suntory Ltd., Arylpiperidinol and arylpiperidine derivatives and drugs containing the same for the treatment of ischemia, convulsions and epilepsy, Patent WO9803172 (1998).
175. Fuso Yakuhin Kogyo KK, Arylpiperidinopropanol and arylpiperazinopropanol derivatives, Patent WO9923072-A (1999).
176. Neurex Corp, Voltage-gated calcium channel antagonist and methods, Patent WO9805780 (1998).
177. Ajinomoto Co. Inc., Oxazepine derivatives and drugs containing the same, Patent WO0040570-A (2000).
178. Ajinomoto Co. Inc., 5,11-Dihydrodibenz[b,e][1,4]-oxazepine derivatives, Patent 2925-A (1999).